Postmenopausal osteoporosis
Second line
Second-line for postmenopausal osteoporosis with high fracture risk after bisphosphonate failure or intolerance per AACE/ACE 2020 and SEIOMM 2024. Dose 60 mg subcutaneously every 6 months. FREEDOM showed 68% reduction in vertebral fracture risk and 40% in hip fracture. After discontinuation, switch to a bisphosphonate to prevent rebound (multiple vertebral fracture risk within 6–18 months of stopping).